- Oops!Something went wrong.Please try again later.
Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"), a company with a proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly.
Jolly began the interview by commenting on a recent press release detailing the Company's involvement in the hypertension market. "What are your thoughts about your company and your valuation going forward?", asked Jolly. "The hypertension market is obviously very large, it has been around a long time, and it is a mature market," explained Bunka before elaborating on the Company's competitors in this sector. "We're all using CBD, but in Lexaria's case we have clinical data that evidences that with our DehydraTECH process CBD absorbs into the body two to five times more effectively," he explained. "So, I think we have a competitive product, a competitive technology, but a mismatch, a dichotomy, in the market valuation."
"We're very excited about pursuing the hypertension market. We have five studies that will be happening this year, three human clinical studies and two animal studies already underway in 2021," said Bunka. "We think there is really going to be a major shift in the way people see us in the months to come."
"There are over a billion people, 1.1 billion, around the world who suffer from hypertension," said Bunka. "This is the silent killer," he added. "It's a huge market and we really believe we have a better solution."
"Could you explain what you are trying to accomplish in the hypertension market with CBD?", asked Jolly. "Only one person in five who has hypertension is actually treating it," explained Bunka. "If everybody who has hypertension was treating it, it would be a much larger market," he continued. "The side effects of most of the drugs used to treat hypertension are so bad that, in some cases, they are worse than the disease itself, including irreversible organ damage to your liver."
"We try to work symbiotically with the body," shared Bunka. "In that vein, the idea of using CBD, cannabidiol, to treat hypertension is really interesting," he said, noting that the Company previously had success lowering blood pressure with 90mg doses of DehydraTECH CBD in a clinical study. "In our upcoming studies we're going to be using 300mg and 450mg doses of CBD, and of course with a stronger dose we're expecting a bigger result," said Bunka. "CBD is really well tolerated by human beings; so even with our new 300mg and 450mg doses, we believe we will be well under the threshold of any negative side effects."
Bunka then elaborated on the Company's potential in revolutionizing the hypertension market, as well as the opportunity this may represent to investors. "Lexaria is only trading at around $5 per share and we only have 5 million shares in existence. We might be the most undervalued biotech company you've ever encountered."
"The work that is coming up in the weeks and months ahead is meant to confirm all of the work that we have been doing for the last three years," said Bunka. "It could be a paradigm shift in the way the world looks at treating hypertension. If we are successful, we believe we will have a path to the world's most efficacious and safe hypertension drug ever developed."
To close the interview, Bunka encouraged listeners and shareholders to do their due diligence and consider the Company's investment potential given their current valuation. "We only just got listed on the NASDAQ in January, most people do not know we exist, we have $9 million in the bank, plenty of money to run the company through the end of 2022, we're in the strongest shape we have ever been, and I don't think there has ever been a better time to own Lexaria than right now," closed Bunka.
To hear Chris Bunka's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7860767-lexaria-bioscience-corp-discusses-potential-of-dehydratech-cbd-for-revolutionary-hypertension-s.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
Stock Day Media
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83269